Status:
UNKNOWN
Prognostic Value of the Right Ventricular Function by Portable Ultrasound in Patients With Pulmonary Hypertension.
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Collaborating Sponsors:
Pamela Mercado Velázquez
Consuelo Orihuela Sandoval
Conditions:
Pulmonary Hypertension
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
Pulmonary arterial hypertension (PAH) is a disease characterized by obliteration and remodeling of small-caliber pulmonary arteries, progressively generating an increase in pulmonary vascular resistan...
Detailed Description
Pulmonary arterial hypertension (PAH) is a disease characterized by obliteration and remodeling of small-caliber pulmonary arteries, progressively generating an increase in pulmonary vascular resistan...
Eligibility Criteria
Inclusion
- Patients with the diagnosis of Pulmonary Hypertension group 1 and 4 by right heart catheterization.
- Presence of a baseline transthoracic echocardiogram as well as a follow-up echocardiogram.
- Presence of 6m baseline walk as well as follow-up.
Exclusion
- All patients with left heart disease associated with PH
- All patients with pulmonary disease associated with PH
- All patients with congenital heart disease who had poor surgical repair.
- Patients who meet the contraindication by the American chest guidelines to perform the 6m walk test.
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2023
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT05343091
Start Date
March 1 2021
End Date
January 31 2023
Last Update
May 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán
Mexico City, Mexico, 14080